A recent study has shown Xolair (Omalizumab) can be used to help facilitate oral desensitization to peanuts.
Peanut allergy is a major problem that affects 1% of the population, as of date, there is no effective therapy. In the news recently, many researchers have been doing oral desensitization to achieve tolerance in patients. There is a risk doing this procedure, as it can trigger anaphylaxis in patients. Xolair (Omalizumab) is a monoclonal anti IgE antibody that has been approved for Moderate to Severe Persistent Asthma. Studies have shown that using Xolair during desensitization diminished the clinical symptoms one may experience during the treatment. Oral desensitization occurred more rapidly and with greater success. Pretreatment with xolair increased the threshold of sensitivity to oral peanut challenge. This may be a future treatment option for the more severe peanut allergic patients.